We present a rare case of rapidly enlarging inflamematory hepatocellular adenoma (IHCA) in a 60-year-old Japanese man. Screening abdominal computed tomography (CT) for the fatty liver patient revealed a 1.7-cm liver m...We present a rare case of rapidly enlarging inflamematory hepatocellular adenoma (IHCA) in a 60-year-old Japanese man. Screening abdominal computed tomography (CT) for the fatty liver patient revealed a 1.7-cm liver mass in the anterior segment of the liver. After 19 months, the lesion had rapidly enlarged to 6 cm in diameter and the patient was referred to our hospital. On perflubutane microbubble contrast-enhanced ultrasonography, the tumor showed a characteristic centripetal filling pattern in the vascular phase. We performed hepatic anterior segment resection because we could not rule out malignant tumor. Histopathological examination showed hyperplasia of mildly atypical hepatocytes and sinusoidal dilatation with marked inflammatory cell infiltration. Immunohistological staining revealed positive staining for serum amyloid A and C-reactive protein;therefore, we diagnosed this tumor as IHCA. The patient remains alive 42 months after operation without evidence of recurrence.展开更多
This review provides an overview of articles about peritoneal mesothelioma(PM)to analyze the effect of treatment modalities on response rates,post-treatment side effects,morbidity and mortality,and survival.Median sur...This review provides an overview of articles about peritoneal mesothelioma(PM)to analyze the effect of treatment modalities on response rates,post-treatment side effects,morbidity and mortality,and survival.Median survival in months following systemic chemotherapy(SC)ranged from 8.7 to 26.8 months.However,no patient was reported to have survived for more than five years with SC alone.In contrast,comprehensive treatment that included cytoreductive surgery(CRS)+perioperative chemotherapy(POC)showed a significantly longer median survival time than SC alone.Additionally,CRS+POC demonstrated 10-year survival rates of 12%-35%.Accordingly,CRS+POC is an innovative treatment that provides long-term survival in selected patients with PM.Selection criteria are performance status(ECOG PS≤1),the absence of extraperitoneal metastasis,PCI less than cutoff levels(from<10 to<28),MIB-1 index(<10),and histologic type(epithelioid type).Postoperative morbidity and mortality rates after CRS+POC were significantly higher than with more conventional operations.Accordingly,CRS and POC should be done at the specialized peritoneal surface malignancy centers.展开更多
文摘We present a rare case of rapidly enlarging inflamematory hepatocellular adenoma (IHCA) in a 60-year-old Japanese man. Screening abdominal computed tomography (CT) for the fatty liver patient revealed a 1.7-cm liver mass in the anterior segment of the liver. After 19 months, the lesion had rapidly enlarged to 6 cm in diameter and the patient was referred to our hospital. On perflubutane microbubble contrast-enhanced ultrasonography, the tumor showed a characteristic centripetal filling pattern in the vascular phase. We performed hepatic anterior segment resection because we could not rule out malignant tumor. Histopathological examination showed hyperplasia of mildly atypical hepatocytes and sinusoidal dilatation with marked inflammatory cell infiltration. Immunohistological staining revealed positive staining for serum amyloid A and C-reactive protein;therefore, we diagnosed this tumor as IHCA. The patient remains alive 42 months after operation without evidence of recurrence.
文摘This review provides an overview of articles about peritoneal mesothelioma(PM)to analyze the effect of treatment modalities on response rates,post-treatment side effects,morbidity and mortality,and survival.Median survival in months following systemic chemotherapy(SC)ranged from 8.7 to 26.8 months.However,no patient was reported to have survived for more than five years with SC alone.In contrast,comprehensive treatment that included cytoreductive surgery(CRS)+perioperative chemotherapy(POC)showed a significantly longer median survival time than SC alone.Additionally,CRS+POC demonstrated 10-year survival rates of 12%-35%.Accordingly,CRS+POC is an innovative treatment that provides long-term survival in selected patients with PM.Selection criteria are performance status(ECOG PS≤1),the absence of extraperitoneal metastasis,PCI less than cutoff levels(from<10 to<28),MIB-1 index(<10),and histologic type(epithelioid type).Postoperative morbidity and mortality rates after CRS+POC were significantly higher than with more conventional operations.Accordingly,CRS and POC should be done at the specialized peritoneal surface malignancy centers.
